HybridSPE®-Phospholipid solid phase extraction (SPE) Cartridge

Description

• General description: HybridSPE-Phospholipid technology is a simple and generic sample prep platform designed for the gross level removal of endogenous protein and phospholipid interferences from biological plasma and serum prior to LC-MS or LC-MS/MS analysis. Biological plasma or serum is first subjected to protein precipitation via the addition and mixing of acidified acetonitrile. Precipitated proteins are then removed by centrifugation and the resulting supernatant is loaded on the HybridSPE-Phospholipid 96-well plate or cartridge which acts as a chemical filter that specifically targets the removal of endogenous sample phospholipids. The phospholipid retention mechanism is based on a highly selective Lewis acid-base interaction between the proprietary zirconia ions functionally bonded to the HybridSPE-Phospholipid stationary phase and the phosphate moiety consistent with all phospholipids. The resulting eluent is ready for immediate LC-MS or LC-MS-MS analysis.The "In-well" and "In-cartridge" precipitation methods are available for the HybridSPE-Phospholipid 96-well version and HybridSPE-Phospholipid Ultra cartridge in which biological plasma/serum is first added to either the well or cartridge, followed by acidified acetonitrile (precipitation agent). After a brief mixing/vortexing step, vacuum is applied. Because the 96-well and Ultra cartridge versions contain a series of low porosity hydrophobic filters/frits, the packed-bed filter/frit assembly acts as a depth filter facilitating the concurrent removal of both phospholipids and precipitated proteins during the extraction process. Standard HybridSPE-Phospholipid cartridges require an "off-line" precipitation method.
• Application: Less is more: a methodological assessment of extraction techniques for per- and polyfluoroalkyl substances (PFAS) analysis in mammalian tissues.: This study evaluates various extraction techniques, including the use of HybridSPE-Phospholipid, for analyzing PFAS in mammalian tissues. The research highlights the importance of effective phospholipid removal to ensure accurate PFAS quantification (Mertens et al., 2023).Rapid analysis of 65 pharmaceuticals and 7 personal care products in plasma and whole-body tissue samples of fish using acidic extraction, zirconia-coated silica cleanup, and liquid chromatography-tandem mass spectrometry.: The study includes HybridSPE-Phospholipid as part of the cleanup process, demonstrating its efficiency in removing phospholipids to improve the detection of pharmaceuticals and personal care products in biological samples (Tanoue et al., 2020).Multi LC-MS/MS and LC-HRMS Methods for Determination of 24 Mycotoxins including Major Phase I and II Biomarker Metabolites in Biological Matrices from Pigs and Broiler Chickens.: This research utilizes HybridSPE-Phospholipid for the cleanup of biological matrices, enhancing the accuracy of mycotoxin detection by effectively removing interfering phospholipids (Lauwers et al., 2019).Effective phospholipid removal from plasma samples by solid phase extraction with the use of copper (II) modified silica gel cartridges.: The study compares various phospholipid removal techniques, highlighting the performance of HybridSPE-Phospholipid in achieving high phospholipid removal efficiency from plasma samples (Flieger et al., 2017).Liquid chromatography mass spectrometry determination of perfluoroalkyl acids in environmental solid extracts after phospholipid removal and on-line turbulent flow chromatography purification.: The research demonstrates the application of HybridSPE-Phospholipid in the removal of phospholipids from environmental solid extracts, facilitating the accurate measurement of perfluoroalkyl acids (Mazzoni et al., 2016).
• Features and Benefits: Merges the simplicity of protein precipitation and the selectivity of SPE via the targeted removal of phospholipidsReduce ion-suppression through the complete removal of phospholipids and precipitated proteins2-3 step generic procedureMinimal to no method developmentAvailable in 96-well and 1 mL cartridge dimensions
• Legal Information: HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany